Calamos Advisors
RARX

Calamos Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Calamos Advisors’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-122,600
Closed -$5.89M – 801
2020
Q1 		$5.89M Buy
122,600
+15,100
+14% +$702K 0.05% 369
2019
Q4 		$5.04M Buy
+107,500
New +$4.75M 0.02% 523

Other funds holding RARX

Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Calamos Advisors's RARX Position: Q2 2020 in Review

Calamos Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 122,600 shares — an estimated $5.89M sold.

Calamos Advisors first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $5.89M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • Calamos Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Calamos Advisors sold 122,600 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $5.89M.
  • Calamos Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Calamos Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $5.89M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Calamos Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.